We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

31 hedge funds and large institutions have $2.56M invested in CASI Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

12% more capital invested

Capital invested by funds: $2.29M → $2.56M (+$277K)

11% more funds holding

Funds holding: 28 → 31 (+3)

Holders
31
Holders Change
+3
Holders Change %
+10.71%
% of All Funds
0.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$38.1K
2
Renaissance Technologies
Renaissance Technologies
New York
+$11.2K
3
MC
Moors & Cabot
Massachusetts
+$7.76K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$2.51K
5
WJA
Williams Jones & Associates
New York
+$2.17K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$18K
2
UBS Group
UBS Group
Switzerland
-$4.2K
3
BFA
BlackRock Fund Advisors
California
-$492

CASI Hedge Fund Activity: Q2 2016 in Review

31 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q2 2016, worth a combined $2.56M — up 12% from $2.29M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new CASI positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $38.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $18K sold.

  • 31 institutional investors held CASI Pharmaceuticals (CASI) as of Q2 2016, up from 28 in Q1 2016.
  • Funds reported $2.56M of CASI Pharmaceuticals stock for Q2 2016, up 12% quarter-over-quarter.
  • 5 funds opened new CASI Pharmaceuticals positions in Q2 2016 and 2 closed out, a net change of +3 holders.
  • The largest CASI Pharmaceuticals buyer in Q2 2016 was Goldman Sachs, an estimated $38.1K added.
  • The largest CASI Pharmaceuticals seller in Q2 2016 was Citadel Advisors, an estimated $18K sold.

Based on aggregated 13F filings for Q2 2016.